We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

New Jersey District Court Rules For Ranbaxy In Glaxo Patent Suit

Law360 (April 7, 2004, 12:00 AM EDT) -- The U.S. District Court for the District of New Jersey has ruled that Ranbaxy Laboratories’ generic version of GlaxoSmithKline's antibiotic Ceftin does not infringe patents held by Glaxo.

The Indian generic drug maker has been selling its antibiotic, cefuroxime axetil, since 2001, when a federal appeals court vacated a preliminary injunction GlaxoSmithKline had won from a lower court in October 2000, according to Ranbaxy.

Ceftin had global sales of $404 million in 2003, GlaxoSmithKline said.

Ranbaxy reported U.S. cefuroxime axetil sales of $134.8 million in 2003....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.